Form EFFECT LIGHTPATH TECHNOLOGIES
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | July 23, 2026 |
| Accession Number: | 0001437749-26-024160 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Duchenne Muscular Dystrophy Clinical Trials Update 2026: Phase-Wise Pipeline Status, Drug Profiles, and Key Developers by DelveInsight | Vertex Pharma, Bioleaders Corporation, Wave Life Sciences
- Advanced Melanoma Clinical Trial Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
- AM Best to Host Networking Reception at International Association of Insurance Supervisors’ Annual Conference in Hong Kong
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share